Skip to main content

Table 2 Summary of response rates

From: A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer

Response Rates

Gemcitabine +Cisplatin

Gemcitabine + Carboplatin

Overall

N = 21

N = 24

Progression #(%)

10 (63)

7(44)

Complete response #(%)

2(13)

3(19)

Partial response #(%)

2(13)

3(19)

Stable disease #(%)

2(13)

3(19)

Discontinued due to toxicity #(%)

5(24)

8(33)

Objective response rate (PR + CR + SD) #(%)

6(38)

9(56)

Mean time to progression (months) [# ± SD (Range)] p = 0.03

7.2 [±2(3.2–9.7)]

5.1 [±1.7(2.3–7.2)]

Response Rates

Gemcitabine +Cisplatin

Gemcitabine + Carboplatin

Platinum Sensitive

N = 10

N = 17

Progression #(%)

6(75)

4(33)

Complete response #(%)

1(13)

3(25)

Partial response #(%)

0(0)

3(25)

Stable disease #(%)

1(13)

2(17)

Discontinued due to toxicity #(%)

2(20)

5(29)

Objective response rate (PR + CR + SD) #(%) p = 0.05

2(25)

8(67)

Mean time to progression (months) [# ± SD (Range)]

7.2 [±2.5(3.2–9.5)]

5.1 [±1.8(2.3–7.2)]

Response Rates

Gemcitabine +Cisplatin

Gemcitabine + Carboplatin

Platinum Resistant

N = 10

N = 7

Progression #(%)

3(43)

3(75)

Complete response #(%)

1(14)

0(0)

Partial response #(%)

2(29)

0(0)

Stable disease #(%)

1(14)

1(25)

Discontinued due to toxicity #(%)

3(30)

3(75)

Objective response rate (PR + CR + SD) #(%)

4(57)

1(25)

Mean time to progression (months) [# ± SD (Range)]

7.2 [±1.6(5.7–9.7)]

5.1 [±1.8(2.5–6.8)]

  1. Abbreviations: SD Standard deviation, PR Partial response, CR Complete response, SD Stable disease